BRCA1 Mutation: An Insidious Enemy with Multiple Facets …

We present here the case of a 59-year-old woman who developed a left breast cancer in 2014 treated by conservative surgery, radiotherapy, and endocrine therapy with letrozole. The diagnosis ofBRCA1 mutation was performed in 2015. In 2018, the patient was referred to our institution for treatment of an aggressive angiosarcoma developed in the same breast. She had undergone radical hysterectomy by the age of 49 years for a benign uterine pathology. In 2020, she developed a tumor in the gastric wall; histological analysis confirmed a serous papillary carcinoma of ovarian origin. She was treated – after gastrectomy and lymphadenectomy – with 6 courses of carboplatin and paclitaxel followed by olaparib therapy. In 2021, she suffered from a chest recurrence of high grade angiosarcoma. New resection with free margins was performed. We discuss the link between angiosarcomas and BRCA mutatio ns, the therapeutic options for angiosarcoma and ovarian cancer of extra ovarian origin and the follow-up modalities.Case Rep Oncol 2022;15:238 –244
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research